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Objective. To examine the relationship between maternal glucose levels and intrauterine fetal adiposity distribution in women with
a normal oral glucose tolerance test (OGTT) at 28 weeks gestation. Study Design. We recruited 231 women with a singleton
pregnancy. At 28 and 37 weeks gestation, sonographic measurements of fetal body composition were performed. Multiple
regression analysis was used to study the inﬂuence of diﬀerent maternal variables on fetal adiposity distribution. Results. Maternal
glucose levels correlated with the fetal abdominal subcutaneous tissue measurements (r = 0.2; P = 0.014) and with birth
weight (r = 0.1; P = 0.04). Maternal glucose levels did not correlate with the fetal mid-thigh muscle thickness and mid-thigh
subcutaneous tissue measurements. Conclusion. We found that in nondiabetic women maternal glucose levels not only inﬂuence
fetaladiposityandbirthweight,butalsoinﬂuencethedistributionoffetaladiposity.Thissupportspreviousevidencethatmaternal
glycemia is a key determinant of intrauterine fetal programming.
1.Introduction
Gestational diabetes mellitus (GDM) has been associated
with increased birth weight and fetal macrosomia [1].
Increasedbirthweightisassociatedwithincreasesintherates
of instrumental vaginal delivery, cesarean section, perineal
trauma, and postpartum haemorrhage [2, 3]. Fetal macro-
somia increases the risk of shoulder dystocia, brachial plexus
injury, intrapartum death, admissions to the neonatal unit,
and newborn metabolic problems, including hypoglycemia
[4]. Large babies are also predisposed to childhood obesity
and to increased morbidity in later life such as hypertension,
insulin resistance, and diabetes mellitus [5, 6].
Recently, the Hyperglycaemia and Adverse Pregnancy
Outcomes (HAPO) study found that in 25,505 women
with a normal oral glucose tolerance test (OGTT) at 24–
32 weeks gestation, maternal glycemia is associated with
a birth weight >90th centile and with neonatal adiposity
measured using skinfold callipers postnatally [7, 8]. These
ﬁndings provided further support for the importance of the
intrauterine environment in programming lifelong health
and raise the possibility that optimizing maternal glycemia
may improve pregnancy outcomes [5].
Over the past 20 years, several investigators have exam-
ined the role of fetal soft-tissue measurements in the
evaluation of fetal growth abnormalities [9]. Fetal adiposity
approximately increases tenfold between 19 and 40 weeks
gestation [10] .A sar e s u l to fa c c e l e r a t e dr a t eo fg r o w t hi n
late gestation, measurements of the fetal adiposity, as well
as estimates of fetal weight, may potentially be useful in the
evaluation of fetal growth abnormalities [9]. The purpose of
this study was to examine the relationship between maternal
glucose levels at 28 weeks gestation and intrauterine fetal
adiposity distribution in women with a normal OGTT.
2.MaterialsandMethods
We conducted a longitudinal prospective observational
study in a large university teaching hospital. To minimize2 Experimental Diabetes Research
confounding variables, the study was conﬁned to white
European women with a singleton pregnancy. Women with
chronic medical problems that predispose to abnormal
intrauterine growth were excluded as well as cases of known
congenital fetal malformations.
Women were enrolled at their convenience between July
2008 and December 2009 when they presented for an OGTT.
It is hospital practice to selectively screen for GDM at 28
weeks gestation, based on risk factors [11]. A normal glucose
response in pregnancy was deﬁned as a fasting value of
<5.3mmol/L, a 1-hour postprandial value of <10.0mmol/L,
a 2-hour postprandial value of <8.6mmol/L and a 3-hour
postprandial value of <7.8mmol/L after a 3-hour 100g
OGTT [12].
All the women enrolled had an early pregnancy ultra-
sound scan previously to conﬁrm gestational age. In early
pregnancy weight and height had been measured digitally
in a standardized way, and the body mass index (BMI)
calculated [13]. At recruitment, maternal weight was again
measured and sonographic evaluation of fetal body com-
position was carried out by one operator (NF) using a
transabdominal curved array transducer on an ALOKA
prosound α7. The fetal head circumference (HC), biparietal
diameter (BPD), abdominal circumference (AC), and femur
length (FL) were measured.
The fetal abdominal subcutaneous tissue was measured
on the anterior abdominal wall in millimetres anterior to the
marginsoftheribs,usingmagniﬁcationattheleveloftheAC
[14]. The fetal mid-thigh muscle thickness was measured at
thelevelofthefemurdiaphysisasthedistancefromtheouter
border of the femur to the inner edge of the subcutaneous
layer. The fetal mid-thigh subcutaneous tissue was calculated
by subtracting the distance from the outer border of the
femur to the outer border of the subcutaneous layer from
the thigh muscle. At 37 weeks gestation, maternal weight
and fetal body composition were measured again by same
operator (NF). Birth weight was measured at delivery. The
clinical outcomes of the pregnancy were obtained from the
obstetric records.
Statistical analysis was performed using SPSS version
15.0 (SPSS Inc. Chicago, Ill, USA). Relevant descriptive
statistics (mean, standard deviation and percentages) were
obtained for the study population. All the variables were
checked for normality using the Kolmogorov-Smirnov test.
The relationship of fetal body composition measurements
and birth weight to a range of possible explanatory variables
was investigated, in the ﬁrst instance, by use of Pearson
correlation coeﬃcients. Explanatory variables identiﬁed as
signiﬁcant in this bivariate analysis were subsequently
entered into a multiple regression model. Trajectories were
tested using repeated measures ANOVA with the predictors
identiﬁed in the regression analysis.
To determine whether there is a sex diﬀerence in the
fetal parameters measured the independent Student’s t-test
was used. The 5% level of signiﬁcance was used throughout.
Written informed consent was obtained and the study was
approved by the Hospital Research and Ethics Committee.
In a sample of 25 women, two measurements of the fetal
abdominal subcutaneous tissue, mid-thigh muscle thickness
and mid-thigh subcutaneous tissue were carried out 5
minutes apart. The test-retest reliability, based on Bland-
Altmananalysis,forthefetalabdominalsubcutaneoustissue,
mid-thigh muscle thickness and mid-thigh subcutaneous
tissue measurements yielded limits of agreement of (−0.64,
0.74), (−1.03, 1.08), and (−0.77, 0.65), respectively, with
coeﬃcients of repeatability of 10.0%, 7.5%, and 11.5%
respectively [15].
3. Results
In total, 320 women were initially enrolled into the study of
which 61 women did not attend for a second visit assessment
at37weeksgestation.Ofthosewomenthatdidnottoattend,
20 women delivered before their second assessment visit at
37 weeks gestation. In the group of women that attended for
their second assessment, 28 women were excluded from the
study because of an abnormal OGTT.
The mean age of the ﬁnal study population (n = 231)
was 30.6 ± 4.8 years with 41.1% (n = 95) primigravidas.
The mean gestation at the ﬁrst antenatal visit was 12.3 ±
1.6 weeks and the mean early pregnancy BMI was 28.2 ±
6.0kg/m2. Of the women studied, 36.4% (n = 84) had a
normal BMI, 28.6% (n = 66) were overweight, and 34.7%
(n = 81) were obese according to the WHO classiﬁcation.
The mean birth weight was 3.7 (±0.5)kg and 3.9% of the
babies had a birth weight ≥4.5kg. The characteristics and
outcomes of the study population are shown in Table 1.
At the normal OGTT, the maternal fasting and one-
hour postprandial glucose levels correlated positively with
maternal early pregnancy BMI (r = 0.2; P<0.001). The
fasting and one-hour postprandial glucose levels did not
correlate with maternal age, parity, height, and gestational
weightgain(GWG)betweenbookingand28weeksgestation.
The two-hour postprandial glucose level correlated with
maternal age and early pregnancy BMI (r = 0.2 and 0.1; P =
0.016 and 0.04, resp.). The three-hour postprandial glucose
level correlated with maternal height and GWG between the
booking visit and 28 weeks gestation (r = 0.2 and 0.1; P =
0.016 and 0.046, resp.).
There were no diﬀerences in the mean maternal age,
height, early pregnancy weight, and BMI between women
with a male fetus and women with a female fetus. There
were also no diﬀerences in maternal gestational weight gain
between booking and recruitment and between recruitment
and 37 weeks gestation between the two groups. We also
found no diﬀerences in the maternal blood sugars between
thetwogroups.Therewas,however,adiﬀerenceintheparity
between the two groups (P = 0.001). In the fetal parameters
measured there were no sex diﬀerences in the abdominal
subcutaneous tissue, mid-thigh muscle thickness and mid-
thigh subcutaneous tissue measurements at 28 and 37 weeks
gestation (Table 2). We also found no sex diﬀerences in the
birth weight (Table 2).
The mean fetal abdominal subcutaneous tissue, mid-
thigh muscle thickness and mid-thigh subcutaneous tissue
measurements at 28 weeks gestation were 3.4 ± 0.8, 7.7 ± 1.7
and 2.9 ± 0.9mm, respectively. Table 3 shows the correlationExperimental Diabetes Research 3
Table 1: Characteristics of the study participants, their newborn, and frequency of outcomes (n = 231).
Maternal characteristics Frequency (%) Mean ± SD Range
Age (years) 30.6 ± 4.8 19.0–41.0
Parity 0.9 ± 1.0 0–4
Early pregnancy BMI (kg/m2) 28.2 ± 6.0 19.1–45.8
Prenatal smoking 14.7
Newborn characteristics
Gestational age at delivery (weeks) 40.2 ± 1.1 36.6–42.0
Birth weight (kg) 3.7 ± 0.5 2.1–5.0
Birth weight >4.5kg 3.9
Male sex 49.8
Obstetric outcomes
Hypertension
Gestational hypertension 10.0
Preeclampsia 3.9
Induction rate 32.4
Caesarean delivery 26.5
BMI: body mass index.
Table 2: Mean values for fetal parameters analysed by fetal sex.
Male fetuses
(n = 124)
Female fetuses
(n = 122) P value
At recruitment (28 weeks)
Abdominal Circumference (mm) 243.5 (14.5) 243.3 (13.8) NS
Abdominal subcutaneous tissue (mm) 3.4 (0.7) 3.4 (0.8) NS
Mid-thigh muscle thickness (mm) 7.7 (1.9) 7.5 (1.6) NS
Mid-thigh subcutaneous tissue (mm) 2.9 (0.9) 2.9 (0.8) NS
At second assessment (37 weeks)
Abdominal circumference (mm) 331.6 (19.4) 333.0 (16.6) NS
Abdominal subcutaneous tissue (mm) 6.4 (1.5) 6.6 (1.3) NS
Mid-thigh muscle thickness (mm) 10.4 (2.8) 10.4 (2.5) NS
Mid-thigh subcutaneous tissue (mm) 5.2 (1.4) 5.0 (1.4) NS
At birth
Gestation (weeks) 40.2 (1.2) 40.2 (1.0) NS
Birth weight (kg) 3.7 (0.5) 3.6 (0.4) NS
between maternal parameters, including blood sugars, and
fetal body composition at 28 weeks gestation.
At 28 weeks gestation, maternal age and the maternal
one-hour postprandial glucose level both inﬂuenced the fetal
abdominal subcutaneous tissue measurement independently
(r2 = 0.095; P<0.001). Maternal age and gestational weight
gain both inﬂuenced the fetal mid-thigh subcutaneous tissue
measurement independently (r2 = 0.065; P = 0.002). Early
pregnancy maternal BMI and fasting glucose levels did not
correlate with any of the fetal body composition parameters.
The mean fetal abdominal subcutaneous tissue mea-
surement, mid-thigh muscle thickness and mid-thigh sub-
cutaneous tissue measurements at 37 weeks gestation were
6.5 ± 1.5, 10.4 ± 2.7, and 5.0 ± 1.6mm respectively.
Table 4 shows the correlation between maternal parameters,
including blood sugars, and fetal body composition at 37
weeks gestation.
At 37 weeks gestation, the fetal AC measurement corre-
latedwithmaternalweightandheightinearlypregnancyand
with maternal fasting and one-hour postprandial glucose
levels at the time of the normal OGTT (Table 4). To
determine which of the variables continued to correlate
with the fetal AC measurement, regression analysis was per-
formed incorporating maternal weight, height, and fasting
and one-hour postprandial glucose levels. In the resulting
regression equation maternal height and fasting and one-
hour postprandial glucose levels continued to be predictive
(r2 = 0.099; P<0.001). The fetal abdominal subcutaneous
tissue measurement correlated with all four maternal glucose
levels. None of the maternal glucose parameters correlated4 Experimental Diabetes Research
Table 3: Correlation between maternal parameters and fetal body composition at 28 weeks gestation (r and P values).
Maternal parameter Fetal AC Fetal abdominal
subcutaneous tissue
Fetal mid-thigh
muscle thickness
Fetal mid-thigh
subcutaneous tissue
Age (years) 0.1 (NS) 0.3 (<0.001) −0.1 (NS) 0.2 (0.005)
Parity 0.0 (NS) 0.1 (NS) 0.0 (NS) 0.0 (NS)
Early pregnancy
Weight (kg) 0.0 (NS) −0.4 (NS) 0.1 (NS) 0.0 (NS)
Height (cm) 0.0 (NS) 0.0 (NS) 0.1 (NS) 0.1 (NS)
BMI (kg/m2) 0.0 (NS) 0.0 (NS) 0.1 (NS) 0.0 (NS)
GWG (1) (kg) 0.1 (NS) 0.0 (NS) 0.1 (NS) 0.2 (0.019)
OGTT glucose levels
fasting 0.0 (NS) 0.1 (NS) 0.0 (NS) 0.0 (NS)
1-hour postprandial 0.1 (NS) 0.2 (0.006) 0.1 (NS) 0.1 (NS)
2-hour postprandial 0.1 (0.026) 0.1 (NS) 0.1 (NS) 0.0 (NS)
3-hour postprandial 0.0 (NS) 0.1 (NS) 0.1 (NS) 0.0 (NS)
AC: abdominal circumference. BMI: body mass index. GWG (1): gestational weight gain per week between the booking visit and 28 weeks gestation. OGTT:
oral glucose tolerance test.
Table 4: Correlation between maternal parameters and fetal body composition at 37 weeks gestation (r and P values).
Maternal parameter Fetal AC Fetal abdominal
subcutaneous tissue
Fetal mid-thigh
muscle thickness
Fetal mid-thigh
subcutaneous tissue
Age (years) 0.1 (NS) 0.1 (NS) −0.1 (NS) 0.0 (NS)
Parity 0.1 (NS) 0.0 (NS) 0.0 (NS) 0.0 (NS)
Early pregnancy
Weight (kg) 0.2 (0.006) 0.0 (NS) 0.1 (NS) 0.1 (NS)
Height (cm) 0.2 (0.007) −0.1 (NS) 0.1 (NS) 0.1 (NS)
BMI (kg/m2) 0.1 (NS) 0.1 (NS) 0.1 (NS) 0.1 (NS)
GWG (1) (kg) 0.1 (NS) 0.0 (NS) 0.1 (NS) 0.1 (NS)
GWG (2) (kg) 0.1 (NS) 0.1 (NS) 0.0 (NS) 0.2 (0.003)
OGTT glucose levels
fasting 0.2 (0.002) 0.2 (0.006) 0.0 (NS) 0.0 (NS)
1-hour postprandial 0.2 (0.003) 0.2 (0.002) 0.0 (NS) 0.1 (NS)
2-hour postprandial 0.1 (NS) 0.2 (0.014) 0.0 (NS) 0.1 (NS)
3-hour postprandial 0.1 (NS) 0.2 (0.001) 0.0 (NS) 0.0 (NS)
AC: abdominal circumference. BMI: body mass index. GWG (1): gestational weight gain per week between the booking visit and 28 weeks gestation. GWG
(2): gestational weight gain per week between 28 and 37 weeks gestation. OGTT: oral glucose tolerance test.
with the fetal mid-thigh muscle thickness and mid-thigh
subcutaneous tissue measurements.
The fetal AC trajectories from 28 to 37 weeks gestation
were inﬂuenced by the maternal fasting glucose levels (F
(1,220) = 4.177, P = 0.042). The fetal AC trajectories
were not inﬂuenced by maternal age, early pregnancy BMI,
gestational weight gain and the one-, two- and three-hour
postprandial glucose levels. The fetal abdominal subcuta-
neoustissuetrajectoriesfrom28and37weeksgestationwere
inﬂuenced by the maternal three-hour postprandial glucose
levels (F (1,218) = 4.732, P = 0.033). The fetal abdominal
subcutaneous tissue trajectories were not inﬂuenced by
maternal age, early pregnancy BMI, gestational weight gain
and the fasting, one and two-hour postprandial glucose
levels. The fetal mid-thigh subcutaneous tissue trajectories
were not inﬂuenced by maternal glucose parameters.
Birth weight correlated with maternal age, height, and
parity (r = 0.2, 0.2 and 0.2; P = 0.024, <0.001 and 0.001
resp.). Birth weight correlated with GWG between the ﬁrst
antenatal visit and 28 weeks gestation (r = 0.2; P = 0.004)
and with GWG between 28 and 37 weeks (r = 0.2; P =
0.015). The maternal fasting (r = 0.1; P = 0.04), one-hour
postprandial (r = 0.2; P = 0.008) and 2-hour postprandial
(r = 0.2; P = 0.003) glucose levels all correlated with birth
weight.
To determine which of the above variables continued
to correlate with birth weight, regression analysis was
performed. The regression equation incorporated maternal
age, parity, smoking habit, height, fasting, and one-hour
postprandial glucose levels, GWG between booking and 28
weeks, GWG between booking and 28 weeks, and gestational
age at delivery. In the resulting regression equation, maternalExperimental Diabetes Research 5
parity, smoking habit, height, one-hour postprandial glucose
level, GWG between booking and 28 weeks, and gestational
age at delivery all continued to be predictive of birth weight
(r2 = 0.306; P<0.001).
4. Discussion
In women where GDM was excluded at the start of the third
trimester, we found that maternal glycemia correlated with
subsequent birth weight. We also found using ultrasound
measurement of fetal soft tissues that maternal glycemia
inﬂuences not only fetal adiposity, but also the distribution
of adipose tissue.
We had a high proportion of obese women in our study
because one of the indications for an OGTT was a maternal
weight >90kg. Although the women were not representative
of our pregnant population, it did, however, allow us to
include obese women who did not have GDM.
In an American study of 220 multiethnic pregnant
women with a normal OGTT, women with a BMI
≥25.0kg/m2 hadheavierbabies(>4.0kg)thanwomenwitha
BMI <25.0kg/m2 [16]. Postnatal measurements of neonatal
skinfold thickness and total body electrical conductivity
estimates of body composition within 72 hours of delivery
found that fetal adiposity increased in women who were
in the overweight/obese BMI categories. However, it was
not possible to comment on the distribution of neonatal
adiposity.
In another study of 33 neonates delivered by women
with a normal BMI and 39 neonates delivered by over-
weight/obese women with singleton pregnancies and a
normalOGTT,birthweight,andneonatalbody composition
were compared [17]. Although there was no diﬀerence in
birth weight between the groups, neonates born to women
with a normal pregravid BMI had less fat mass and greater
fat-free mass than neonates born to women who were
overweight/obese.
Maternal obesity has been shown to eﬀect glucose
metabolism with a loss of the reduction in fasting glucose in
early pregnancy and enhancement of peripheral and hepatic
insulin resistance [18]. We found that maternal glucose
levels, at the time of the normal OGTT, were inﬂuenced
by early pregnancy BMI. However, we also found that the
inﬂuence of maternal glucose on fetal body composition was
independent of maternal BMI.
An Italian group assessed fetal adiposity at 31 and 37
weeks gestation in ﬁfteen well-controlled insulin-dependent
pregnant women and 16 controls with normal glucose [19].
The fasting and postprandial glucose concentrations were
higher in the well-controlled diabetic pregnancies compared
with the controls. They found no diﬀerence in the birth
weight and ponderal index between the two groups. How-
ever, they found that in the diabetic group fetal abdominal
adiposity was increased despite the tight maternal glycemic
control.
Another Italian group compared fetal soft-tissue mea-
surements in 228 mothers with normal and abnormal oral
glucose challenge tests [20]. The mothers were not obese
and did not have GDM. They found that in the women
with an abnormal oral glucose challenge test fetal adiposity
was increased. This study again suggests that any degree
of maternal glycemia represents an altered intrauterine
environment for fetal growth even if less than that required
for the diagnosis of GDM.
While the numbers in our study are not representative
of all pregnant women, it does have strengths. The early
pregnancy calculation of BMI and subsequent weight gain
was based on accurate measurement throughout pregnancy
and was not based on self-reporting [13]. In the HAPO
study, BMI was only recorded at the time of the OGTT,
whichvariedbetween24and32weeksgestation[8].Wewere
also able to standardize GWG based on measurements of
maternal weight at 28 and 37 weeks gestation allowing us to
study the inﬂuence of GWG as well as BMI on fetal adiposity
[21]. Conﬁning our study to white European women with a
singletonpregnancyavoidedpotentialconfoundingvariables
such as ethnicity and multiple pregnancies [22]. All women
in our study had an early pregnancy ultrasound to conﬁrm
gestational age which is a key determinant of estimated fetal
weight in utero and of birth weight. The value of measuring
fetal adiposity at both 28 and 37 weeks gestation rather
thanpostnatallyallowedustostudytherelationshipbetween
maternal glycemia and intrauterine growth avoiding possible
confounding variables such as growth restriction after 37
weeks gestation, neonatal age at measurement and type of
infant feeding.
In adults, excess fat deposited abdominally carries higher
risk of cardiovascular disease than excess fat deposited
in the limbs [23]. Our ﬁnding that maternal glycemia
independently of GDM inﬂuences birth weight, fetal adi-
posity, and the distribution of fetal adiposity strengthens
the possibility that maternal glycemia is a key determinant
of intrauterine fetal programming. What implications the
increased abdominal adiposity has in later life for the baby’s
visceral fat levels and risk of metabolic syndrome, however,
remains uncertain. Further studies are required to assess
whether interventions, such as dietary manipulation, drugs,
or exercise, optimize fetal adiposity and birth weight by
reducing maternal glycemia even in women who do not have
a diagnosis of GDM.
Conﬂict of Interests
Theauthorshavenopotentialconﬂictofintereststodisclose.
Acknowledgment
The authors thank Dr. Tim Grant, Consultant Statistician,
for his advice.
References
[1] E. A. Reece, “The fetal and maternal consequences of
gestational diabetes mellitus,” Journal of Maternal-Fetal and
Neonatal Medicine, vol. 23, no. 3, pp. 199–203, 2010.
[2] M. J. Turner, M. J. Rasmussen, J. E. Turner, P. C. Boylan, D.
MacDonald, and J. M. Stronge, “The inﬂuence of birth weight6 Experimental Diabetes Research
onlabourinnulliparas,”ObstetricsandGynecology,vol.76,pp.
159–163, 1990.
[ 3 ] X .Z h a n g ,A .D e c k e r ,R .W .P l a t t ,a n dM .S .K r a m e r ,“ H o wb i g
is too big? The perinatal consequences of fetal macrosomia,”
American Journal of Obstetrics and Gynecology, vol. 198, no. 5,
pp. 517.e1–517.e6, 2008.
[4] S. L. Boulet, H. M. Salihu, and G. R. Alexander, “Mode of
delivery and birth outcomes of macrosomic infants,” Journal
of Obstetrics and Gynaecology, vol. 93, pp. 332–346, 2005.
[ 5 ]D .J .P .B a r k e r ,P .D .G l u c k m a n ,K .M .G o d f r e y ,J .E .
Harding, J. A. Owens, and J. S. Robinson, “Fetal nutrition and
cardiovascular disease in adult life,” Lancet, vol. 341, no. 8850,
pp. 938–941, 1993.
[6] A. Plagemann, T. Harder, R. Kohlhoﬀ,W .R o h d e ,a n dG .
D¨ orner, “Overweight and obesity in infants of mothers with
long-terminsulin-dependentdiabetesorgestational diabetes,”
International Journal of Obesity, vol. 21, no. 6, pp. 451–456,
1997.
[7] BE. Metzger, “The HAPO Study Cooperative Research Group.
Hyperglycaemia and adverse pregnancy outcomes,” The New
England Journal of Medicine, vol. 358, pp. 1991–2002, 2008.
[8] HAPO Study Group, “Hyperglycemia and adverse pregnancy
outcome(HAPO)study:associationswithneonatalanthropo-
metrics,” Diabetes, vol. 58, no. 2, pp. 453–459, 2009.
[9] N. Farah, B. Stuart, V. Donnelly, G. Raﬀerty, and M. Turner,
“What is the value of ultrasound soft tissue measurements in
the prediction of abnormal fetal growth?” Journal of Obstetrics
and Gynaecology, vol. 29, no. 6, pp. 457–463, 2009.
[10] I. M. Bernstein, M. I. Goran, S. B. Amini, and P. M. Catalano,
“Diﬀerential growth of fetal tissues during the second half
of pregnancy,” American Journal of Obstetrics and Gynecology,
vol. 176, no. 1 I, pp. 28–32, 1997.
[11] N. Farah, B. Stuart, E. Harrold, C. Fattah, M. Kennelly, and M.
J. Turner, “Are there sex diﬀerences in Fetal Abdominal Sub-
cutaneous Tissue (FAST) measurements?” European Journal of
Obstetrics Gynecology and Reproductive Biology, vol. 148, no. 2,
pp. 118–120, 2010.
[12] American Diabetes Association, “Diagnosis and classiﬁcation
of diabetes mellitus,” Diabetes Care, vol. 27, pp. 5–10, 2004.
[ 1 3 ]C .F a t t a h ,N .F a r a h ,F .O ’ T o o l e ,S .B a r r y ,B .S t u a r t ,a n dM .
J. Turner, “Body Mass Index (BMI) in women booking for
antenatal care: comparison between selfreported and digital
measurements,” European Journal of Obstetrics Gynecology and
Reproductive Biology, vol. 144, no. 1, pp. 32–34, 2009.
[14] F. Gardeil, R. Greene, B. Stuart, and M. J. Turner, “Subcu-
taneous fat in the fetal abdomen as a predictor of growth
restriction,” Obstetrics and Gynecology, vol. 94, no. 2, pp. 209–
212, 1999.
[15] J. M. Bland and D. G. Altman, “Statistical methods for assess-
ingagreementbetweentwomethodsofclinicalmeasurement,”
Lancet, vol. 1, no. 8476, pp. 307–310, 1986.
[16] M. F. Sewell, L. Huston-Presley, D. M. Super, and P. Catalano,
“Increased neonatal fatmass,notlean bodymass,isassociated
with maternal obesity,” American Journal of Obstetrics and
Gynecology, vol. 195, no. 4, pp. 1100–1103, 2006.
[17] H. R. Hull, M. K. Dinger, A. W. Knehans, D. M. Thompson,
and D. A. Fields, “Impact of maternal body mass index
on neonate birthweight and body composition,” American
Journal of Obstetrics and Gynecology, vol. 198, no. 4, pp.
416.e1–416.e6, 2008.
[18] M. M. Avram, A. S. Avram, and W. D. James, “Subcutaneous
fat in normal and diseased states. 3. Adipogenesis: from
stem cell to fat cell,” Journal of the American Academy of
Dermatology, vol. 56, no. 3, pp. 472–492, 2007.
[19] P. Greco, A. Vimercati, J. Hyett et al., “The ultrasound
assessment of adipose tissue deposition in fetuses of ‘well
controlled’ insulin-dependent diabetic pregnancies,” Diabetic
Medicine, vol. 20, no. 10, pp. 858–862, 2003.
[20] E. Parretti, L. Carignani, R. Cioni et al., “Sonographic evalu-
ation of fetal growth and body composition in women with
diﬀerent degrees of normal glucose metabolism,” Diabetes
Care, vol. 26, no. 10, pp. 2741–2748, 2003.
[21] M. J. Turner and N. Farah, “Gestational weight gain and birth
weight,” Irish Medical Journal, vol. 103, pp. 293–294, 2010.
[22] N. Farah, M. Murphy, N. O’Connor, M. Ramphul, M.
Kennelly, and M. J. Turner, “Diﬀerences in maternal body
composition between women from the Indian Subcontinent
and Irish women,” Journal of Obstetrics and Gynaecology, vol.
31, pp. 483–485, 2011.
[23] L. Lapidus, C. Bengtsson, and B. Larsson, “Distribution of
adipose tissue and risk of cardiovascular disease and death: a
12 year follow up of participants in the population study of
women in Gothenburg, Sweden,” British Medical Journal, vol.
289, no. 6454, pp. 1257–1261, 1984.